Renalytix AI plc Stock News

Let's keep it real in this joint – you should generally avoid stocks under $1. Yes, they're “cheap” but that's not necessarily a good thing.

Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is develo

Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid S

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.

Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ne

BTE, AZEK, SOLO, RNLX and RSKD have been added to the Zacks Rank #1 (Strong Buy) List on October 12, 2023.

Renalytix PLC (AIM:RENX) shares fell 12% to 46.09p after it said newly allowed US patents further strengthen the core intellectual property underpinning its KidneyIntelX blood test technology. The

Renalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raisi

Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for the company's FDA-approved kidneyintelX.dkd test.

Renalytix Plc (NASDAQ:RNLX ) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Thomas McLa

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September

Renalytix PLC (AIM:RENX) shares ramped 7.5% higher to 128.95p on Friday morning after it announced a distribution agreement for its kidneyintelX.dkd with Vector Pharma for the Middle East, a region

Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval and established insurance reimbursement, partnerships, and a sales team. The KidneyIntelX pl

Renalytix (NASDAQ: RNLX ) stock is rising higher on Friday after the medical company got marketing permission from the FDA. According to a press release from Renalytix, the FDA is allowing the company

Renalytix Plc (NASDAQ:RNLX ) Q2 2023 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO O. James Sterling - CFO Thomas McLa